Tebanicline dihydrochloride (Ebanicline dihydrochloride) is a nAChR modulator with effective oral analgesic activity, inhibiting cytisine binding to α4β2 neuronal nAChRs with a Ki of 37 pM [1].

Tebanicline is a novel and effective cholinergic nAChR ligand with analgesic properties and preferential selectivity for neuronal nAChRs. Tebanicline inhibits the binding of cytisine to α4β2 neuronal nAChRs with a Ki of 37 pM. Tebanicline is functionally an agonist. At the transfected human alpha 4 beta 2 neuronal nAChR (K177 cells), with increased 86Rb+ efflux as a measure of cation efflux, Tebanicline had an EC50 value of 140 nM with an intrinsic activity (IA) compared with (-)-nicotine of 130%; at the nAChR subtype expressed in IMR-32 cells (sympathetic ganglion-like), an EC50 of 340 nM (IA = 126%); at the F11 dorsal root ganglion cell line (sensory ganglion-like), an EC50 of 1220 nM (IA = 71%); and via direct measurement of ion currents, an EC50 value of 56,000 nM (IA = 83%) at the human alpha 7 homooligimeric nAChR produced in oocytes.

Tebanicline is a potent analgesic with full efficacy in models of acute and persistent pain and these effects are primarily mediated by an action at central neuronal nAChRs [2]. Tebanicline produces significant analgesic effects in mice in response to acute noxious thermal stimulation. ABT-594 is orally active, but 10-fold less potent by this route than after intraperitoneal injection. The analgesic effect of ABT-594 is blocked, but not reversed, by the noncompetitive neuronal nicotinic acetylcholine receptor antagonist [3]. Tebanicline has analgesic effects in rat models of acute thermal, persistent chemical, and neuropathic pain. Injection of tebanicline directly into the nucleus raphe magnus (NRM) is antinociceptive in a thermal threshold test and disruption of serotonergic neurons in the NRM attenuates the effect of systemic tebanicline [4].